NEW YORK – Amoy Diagnostics announced Wednesday that it has signed an agreement with Merck KGaA to develop a companion diagnostic test in China to support Merck KGaA's novel MET inhibitor tepotinib (Tepmetko).
Tepotinib is a selective small molecule drug designed to inhibit MET in subjects with non-small cell lung cancer and MET alterations.